|Mary Lynn Carver|
Mary Lynn Carver has joined Kite, the Santa Monica-based biopharmaceutical developer of cancer immunotherapies.
Gilead Sciences, which chalked up $25B in fiscal 2020 revenues, acquired Kite in 2017 for $12B.
Carver exited AstraZeneca’s London headquarters as head of global internal communications in 2009. She was posted for nearly a decade in Wilmington (DE) as executive director of corporate communications for AstraZeneca’s global oncology unit.
Following AstraZeneca, Carver was senior VP-strategic communications & PR at St. Jude Children’s Research Hospital (Memphis), senior VP-communications & PA at University of Maryland Medical System (Baltimore) and global chief communications officer at General Mills (Minneapolis).
Carver was recently running her own shop, MLC Strategic Advisors, since the beginning of last year.